Watanabe Keisuke, Shinkai Masaharu, Goto Hideto, Yoshikawa Sumiko, Yamaguchi Nobuhiro, Hara Yuu, Shinoda Masahiro, Moriyama Yusuke, Rubin Bruce K, Ishigatsubo Yoshiaki, Kaneko Takeshi
Tumori. 2013 Jul-Aug;99(4):e172-6. doi: 10.1177/030089161309900428.
For patients with inoperable thymic carcinoma, multidrug chemotherapy containing cisplatin and an anthracycline is often used as first-line chemotherapy. A commonly applied regimen is cisplatin + doxorubicin + vincristine + cyclophosphamide (ADOC). There are relatively few reports on the use of carboplatin and paclitaxel as first-line chemotherapy for thymic carcinoma. In addition, little is known about its efficacy as second-line chemotherapy in patients with advanced thymic carcinoma. We here report on three patients with thymic carcinoma who were treated with carboplatin and paclitaxel as second-line chemotherapy after failure of ADOC. According to the Response Evaluation Criteria in Solid Tumors version 1.1, one patient achieved a partial response and two patients achieved stable disease. The median progression-free survival was 6.7 months and the median overall survival exceeded 3 years. Toxicities were well tolerated. Chemotherapy with carboplatin and paclitaxel appears to be effective as second-line chemotherapy for some persons with thymic carcinoma who fail ADOC.
对于无法手术的胸腺癌患者，含顺铂和蒽环类药物的多药化疗常被用作一线化疗。一种常用的方案是顺铂+阿霉素+长春新碱+环磷酰胺（ADOC）。关于将卡铂和紫杉醇用作胸腺癌一线化疗的报道相对较少。此外，对于其作为晚期胸腺癌患者二线化疗的疗效知之甚少。我们在此报告3例胸腺癌患者，他们在ADOC治疗失败后接受卡铂和紫杉醇作为二线化疗。根据实体瘤疗效评价标准第1.1版，1例患者达到部分缓解，2例患者病情稳定。无进展生存期的中位数为6.7个月，总生存期的中位数超过3年。毒性反应耐受性良好。对于一些ADOC治疗失败的胸腺癌患者，卡铂和紫杉醇化疗作为二线化疗似乎有效。
